LAVAL, QC and CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq:LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company focused on discovering and developing distinctive novel small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases, today reported its financial results for the second quarter ended June 30, 2023.
Read more at prnewswire.comLiminal BioSciences Reports Second Quarter Financial Results 2023
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here